Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

Abstract

Background The reported incidence of Philadelphia‐negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age‐standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000–2014. The age‐standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34–4.56)/100 000 person‐years. The age‐standardized incidence for polycythemia vera was 1.48 (1.42–1.54), for essential thrombocythemia 1.60 (1.53–1.66) and for primary myelofibrosis 0.52 (0.48–0.56)/100 000 person‐years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population‐based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.

The Prevalence of Myeloproliferative Disorders in A Group of Iraqi Patients And Its Relation To Blood Indices Parameters

“…Our study shows male-to-female ratio to be 1.2, which is compatible with a Norwegian study male-to-female ratio is 1.2 for all MPNs [8]. Another Swedish study has shown male-to-female ration as 1.07 [9].…”

“…Regarding PV, our study shows male-to-female ratio to be 2. This is compatible with the US study that shows a ratio of 1.83 [11], while the Swedish study reported a ratio of 1.48 [9].…”

“…Regarding myelofibrosis, in our study, the maleto-female ratio is 2.14. Although it is more prevalent in males, the ratio is higher than that of the Swedish study, in which the ratio is 1.48 [9]. A study that was conducted in the USA has shown that the ratio is 1.83 [11].…”

Aetiology of Myeloproliferative Neoplasms

“…Similarly, incidence of PMF increased slightly over time [ 14 ]. The number of MPN patients who were recorded as unclassified decreased over time demonstrating an improvement in the classification of cases [ 15 ]. Conversely, in Australia, between 2003 and 2014, incidence of MPNs have been seen to decrease by −2.9% per year [ 16 ].…”

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

“…Myeloproliferative neoplasms (MPN) are a collection of clonal hematopoietic stem cell disorders characterized by the proliferation of one of more of the hematopoietic lineages [ 1 , 2 , 3 , 4 ]. The major clinicopathologic entities comprise chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [ 5 , 6 ].…”